Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

Rhea-AI Summary

Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Ron Bentsur, the company's Chairman and CEO, will deliver a presentation on May 20th, 2025, from 10:30 to 11:00 a.m. ET. The presentation will be accessible via webcast for interested investors and stakeholders.

Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference.

Event	3rd Annual H.C. Wainwright BioConnect Investor Conference
Date	May 20th, 2025
Time	10:30 – 11:00 a.m. ET
Link	Nuvectis Pharma Presentation Webcast Link

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.

Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com 

Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com 

FAQ

When is Nuvectis Pharma (NVCT) presenting at the H.C. Wainwright BioConnect Conference 2025?

Nuvectis Pharma (NVCT) will present at the H.C. Wainwright BioConnect Conference on May 20th, 2025, from 10:30 to 11:00 a.m. ET.

Who will represent Nuvectis Pharma (NVCT) at the H.C. Wainwright Conference 2025?

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis Pharma, will represent the company at the conference.

What is Nuvectis Pharma's (NVCT) main business focus?

Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on developing innovative precision medicines for treating serious oncology conditions with unmet medical needs.

How can investors access Nuvectis Pharma's (NVCT) presentation at the H.C. Wainwright Conference?

Investors can access Nuvectis Pharma's presentation through a webcast link provided by the company.